文献速递男科与性医学

尝试受孕夫妇中早期家庭精液分析筛查的成本效益

Cost-effectiveness of Early Screening Home Semen Analysis in Couples Attempting to Conceive.
PubMed 文献 · Urology · 2022-09-14

研究采用决策分析模型,从患者视角比较三种策略:不检测、家庭精液检测试剂盒、诊所金标准实验室精液分析,主要结局为检出少精症(精子浓度<15百万/mL)并计算每节省一个月专科评估时间的增量成本。与不筛查相比,家庭检测节省89,000个月,增量成本$7,418,000,ICMS为$45.51;与家庭检测相比,普遍金标准检测额外节省3000个月,ICMS为$17,691。作者认为广泛采用早期家庭精液分析可能是一种成本效益较好的筛查方法。

要点

  • 与不筛查相比,家庭精液检测每10万患者节省89,000个月至男科评估时间,ICMS为$45.51。
  • 与家庭检测相比,普遍金标准诊所实验室检测额外节省3000个月,ICMS为$17,691。
  • 作者认为广泛采用早期家庭精液分析可能是有成本效益的少精症筛查方法。

核心结论

  • 广泛采用和早期使用家庭精液分析可能是一种筛查少精症并促进男科专科进一步评估的成本效益较好的方法。

研究设计与样本

  • 研究基于医学文献输入构建决策分析模型,索引患者为寻求生育的夫妇中的男性伴侣,模型进入时点假定为夫妇开始通过自然方式尝试受孕之时。

主要发现

  • 与不筛查的基线策略相比,使用家庭检测可节省89,000个月,增量成本为$7,418,000,每10万患者的ICMS为$45.51。
  • 与家庭检测策略相比,转向普遍金标准诊所和实验室检测策略额外节省3000个月,ICMS为$17,691。

关键数值与推荐

  • 少精症定义为精子浓度<15百万/mL。
  • 三种策略为:不检测的基线策略、使用家庭精液检测试剂盒、通过诊所就诊和金标准实验室精液分析的普遍检测。
  • 主要结局为少精症的检出,策略按每10万患者节省的至男性不育专科评估月数排序,成本从患者视角考虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the cost-effectiveness of incorporating home semen analysis in screening for oligospermia and expediting time to evaluation. METHODS: A decision analytic model was built using inputs from the medical literature. The index patient is the male partner in a couple seeking fertility, and entry into the model was assumed to be at the inception of the couple's attempts to conceive via natural means. Three main strategies are described and analyzed: (1) baseline strategy of no testing, (2) utilization of a home semen testing kit, (3) universal testing via a clinic visit and gold standard lab semen analysis. The primary outcome was detection of oligospermia (defined as sperm concentration <15 million/mL). Strategies were ranked by months to evaluation by a male infertility specialist saved. Costs were considered from the patient perspective and were incorporated to determine the incremental cost per month saved to evaluation (ICMS) per 100,000 patients. RESULTS: Compared to a baseline strategy of no screening, utilizing a home test would save 89,000 months at the incremental cost of $7,418,000 for an ICMS of $45.51. Shifting to a strategy of universal gold standard clinic and lab testing saves an additional 3000 months but at an ICMS of $17,691 compared to the home testing strategy. CONCLUSION: Widespread adoption and the early usage of home semen analysis may be a cost-effective method of screening for oligospermia and facilitating further evaluation with an andrology specialist.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Lai JD, Fantus RJ, Meza JA, et al. Cost-effectiveness of Early Screening Home Semen Analysis in Couples Attempting to Conceive. Urology. 2022. PMID: 36115433. doi:10.1016/j.urology.2022.06.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。